What is Lifesci Capital’s Forecast for OKUR FY2025 Earnings?

OnKure Therapeutics (NASDAQ:OKUR) – Analysts at Lifesci Capital issued their FY2025 earnings estimates for OnKure Therapeutics in a research report issued on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky expects that the company will post earnings per share of ($5.14) for the year. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51).

OKUR has been the topic of a number of other research reports. Leerink Partners started coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price target on the stock. Leerink Partnrs raised shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, Oppenheimer dropped their target price on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research report on Tuesday. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $34.33.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR opened at $4.79 on Thursday. OnKure Therapeutics has a 12 month low of $4.57 and a 12 month high of $20.00. The company has a market capitalization of $16.01 million, a price-to-earnings ratio of -0.39 and a beta of 0.28. The company has a 50 day moving average price of $5.90.

Institutional Investors Weigh In On OnKure Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC bought a new stake in OnKure Therapeutics in the 4th quarter valued at $75,000. OMERS ADMINISTRATION Corp bought a new stake in OnKure Therapeutics in the 4th quarter valued at $104,000. Walleye Capital LLC bought a new stake in OnKure Therapeutics in the 4th quarter valued at $116,000. Two Sigma Advisers LP bought a new stake in OnKure Therapeutics in the 4th quarter valued at $122,000. Finally, Shay Capital LLC bought a new stake in OnKure Therapeutics in the 4th quarter valued at $129,000. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.